Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
Thomas Crosby,Chris Nicholas Hurt,Stephen Falk,Simon Gollins,Somnath Mukherjee,John Staffurth,John Staffurth,Ruby Ray,Nadim Bashir,John Bridgewater,J. Ian Geh,David Cunningham,Jane M Blazeby,Rajarshi Roy,Tim Maughan,Gareth Griffiths,Gareth Griffiths +16 more
Reads0
Chats0
TLDR
The addition of cetuximab to standard chemotherapy and radiotherapy cannot be recommended for patients with oesophageal cancer suitable for definitive CRT.Abstract:
Background: Definitive chemoradiotherapy (CRT) is an alternative to surgery for the curative treatment of oesophageal carcinoma. The SCOPE1 trial aimed to investigate the addition of cetuximab to cisplatin and fluoropyrimidine-based definitive CRT in patients with localised oesophageal squamous-cell cancer and adenocarcinomas to assess activity, safety, and feasibility of use.
Methods: In this multicentre, randomised, open-label, phase 2/3 trial, we recruited patients aged 18 years and older from UK radiotherapy centres who had non-metastatic, histologically confirmed carcinoma of the oesophagus (adenocarcinoma, squamous-cell, or undifferentiated; WHO status 0–1; stage I–III disease) and been selected to receive definitive CRT. Patients were randomly assigned (1:1) via a central computerised system using stratified minimisation (with an 80:20 random element) to receive CRT alone or CRT with cetuximab (400 mg/m2 on day 1 followed by 250 mg/m2 weekly), stratified by recruiting hospital, primary reason for not having surgery, tumour histology, and tumour stage. CRT consisted of cisplatin 60 mg/m2 (day 1) and capecitabine 625 mg/m2 twice daily (days 1–21) for four cycles; cycles three and four were given concurrently with 50 Gy in 25 fractions of radiotherapy. The primary endpoint was the proportion of patients who were treatment failure free at week 24 for the phase 2 trial and overall survival for the phase 3 trial, both measured from randomisation. We analysed data by intention to treat. This trial is an International Standard Randomised Controlled Trial, number 47718479.
Findings: 258 patients (129 assigned to each treatment group) from 36 UK centres were recruited between Feb 7, 2008, and Feb 22, 2012. Recruitment was stopped without continuation to phase 3 because the trial met criteria for futility, but we continued to follow-up recruited patients until all had reached at least 24-week follow-up (median follow-up of patients who survived was 16·8 months [IQR 11·2–24·5]). Fewer patients were treatment failure free at 24 weeks in the CRT plus cetuximab group (79 of 119 patients [66·4%, 90% CI 58·6–73·6]) than in the CRT only group (93 of 121 patients [76·9%, 69·7–83·0]). The CRT plus cetuximab group also had shorter median overall survival (22·1 months [95% CI 15·1–24·5] vs 25·4 months [20·5–37·9]; adjusted HR 1·53 [95% CI 1·03–2·27]; p=0·035). Patients who received CRT plus cetuximab had more non-haematological grade 3 or 4 toxicities (102 [79%] of 129 patients vs 81 [63%] of 129 patients; p=0·004). The most common grade 3 or 4 toxicities were low white blood cell count (14 [11%] in the CRT plus cetuximab group vs 21 [16%] in the CRT only group), low absolute neutrophil count (15 [12%] vs 24 [19%]), fatigue (26 [20%] vs 25 [19%]), and dysphagia (35 [27%] vs 37 [29%]).
Interpretation: The addition of cetuximab to standard chemotherapy and radiotherapy cannot be recommended for patients with oesophageal cancer suitable for definitive CRT.read more
Citations
More filters
Journal Article
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Journal ArticleDOI
Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma
TL;DR: Advances in diagnostic techniques such as magnifying endoscopy with narrow band imaging or positron emission tomography have increased the accuracy of diagnosis of ESCC and advances gained from basic and clinical research are reviewed.
Journal ArticleDOI
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
John N. Primrose,Stephen Falk,M Finch-Jones,Juan W. Valle,Derek A. O'Reilly,Ajith K. Siriwardena,Joanne Hornbuckle,M Peterson,Myrddin Rees,Timothy Iveson,Tamas Hickish,Rachel Butler,Louise Stanton,Elizabeth Dixon,Louisa Little,Megan Bowers,S Pugh,O. J. Garden,David Cunningham,Tim Maughan,John Bridgewater +20 more
TL;DR: This trial aimed to assess the benefit of addition of cetuximab to standard chemotherapy in patients with resectable colorectal liver metastasis and met protocol-defined futility criteria, and the primary endpoint was progression-free survival.
Journal ArticleDOI
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo,Yasuo Hamamoto,Ken Kato,Takashi Ura,Takashi Kojima,Takahiro Tsushima,Shuichi Hironaka,Hiroki Hara,Taroh Satoh,Satoru Iwasa,Kei Muro,Hirofumi Yasui,Keiko Minashi,Kensei Yamaguchi,Atsushi Ohtsu,Yuichiro Doki,Yuko Kitagawa +16 more
TL;DR: Nivolumab showed promising activity with a manageable safety profile and could offer a potential new treatment approach for patients with treatment-refractory advanced squamous-cell carcinoma.
Journal ArticleDOI
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial
Thierry Conroy,Marie-Pierre Galais,Jean-Luc Raoul,Olivier Bouché,Sophie Gourgou-Bourgade,Jean-Yves Douillard,Pierre-Luc Etienne,Valérie Boige,Isabelle Martel-Lafay,Pierre Michel,Carmen Llacer-Moscardo,Eric Francois,Gilles Créhange,Meher Ben Abdelghani,Beata Juzyna,Laurent Bedenne,Antoine Adenis +16 more
TL;DR: The PRODIGE5/ACCORD17 trial aimed to assess the efficacy and safety of the FOLFOX treatment regimen versus fluorouracil and cisplatin as part of chemoradiotherapy in patients with localised oesophageal cancer.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Neil K. Aaronson,Sam H Ahmedzai,Bengt Bergman,Monika Bullinger,Ann Cull,Nicole Duez,Antonio Filiberti,Henning Flechtner,Stewart B. Fleishman,Johanna C. J. M. de Haes,Stein Kaasa,M. Klee,David Osoba,Darius Razavi,Peter B. Rofe,Simon Schraub,Kommer C. A. Sneeuw,Marianne Sullivan,Fumikazu Takeda +18 more
TL;DR: The reliability and validity of the EORTC QLQ-C30 questionnaire were highly consistent across the three language-cultural groups studied: patients from English-speaking countries, Northern Europe, and Southern Europe.
Journal ArticleDOI
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang,Eric Van Cutsem,A. Feyereislova,Hyun Cheol Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,G. Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang +15 more
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham,Yves Humblet,Salvatore Siena,David Khayat,Harry Bleiberg,Armando Santoro,D. Bets,M. Mueser,Andreas Harstrick,Chris Verslype,Ian Chau,Eric Van Cutsem +11 more
TL;DR: Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.